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Fig. 1 (abstract P149). Flow diagram showing patient disposition
throughout the trial
Fig. 2 (abstract P149). Multivariate analysis using random forest
showing sorted variable importance (VI) mean VI (on the X-axis) of
all variables recorded , in descending order (on the y-axis). The red
line is the threshold value. Only five items were above the line but
with minor significance, of no clinical relevance (VI mean < 0.002).
Variables legend: V2: Current age, V3: Gender, V5: Age of Onset, V6:
Episodic CH, V7: Chronic CH, V8: Probable CH , V9: Strictly Unilateral,
V10: Side Variable, V11: Bilateral, V12: Site RetroOrbital,V13: Site Orbital,
V14: Site Frontal, V15: Site Temporal, V16: Site Parietal, V17: Site Vertex,
V18: Site Occiput, V19: Site Nasal, V20: Absence of dysautonomic
feature, V21: Ptosis, V22: Eye Oedema, V23: Conjonctival injection, V24:
Miosis, V25: Lacrimation, V26: Nasal Blockage, V27: Rhinorrea, V28:
Sweating, V29: Facial Flush, V30: Aural Fullness, V31: Restlessness, V32:
Average attack frequency per day, V33: Minimum attack frequency per
day V34: Maximum attack frequency per day, V35: Average Attack
Duration, V36: Minimum Attack Duration, V37: Maximum Attack
Duration, V39: Intractable to Acute treatment, V40: Intractable to
The Journal of Headache and Pain 2018, 19(Suppl 1):80 Page 116 of 147P149
Is pituitary screening necessary in cluster headache?
Lou Grangeon1,2, Emer O’Connor1, Daisuke Danno1, Thanh Mai Pham
Ngoc3, Indran Davagnanam4, Manjit Matharu1
1Headache Group, UCL Institute of Neurology and The National Hospital
for Neurology and Neurosurgery, Queen Square, London; 2Department
of Neurology, Rouen University Hospital, 76031, Rouen, France;
3Mathematics Institute of Orsay, Paris Sud University, CNRS, 91405 Orsay,
France; 4Department of Brain Repair and Rehabilitation, UCL Institute of
Neurology, Queen Square, London
Correspondence: Manjit Matharu (m.matharu@uclmail.net)
The Journal of Headache and Pain 2018, 19(Suppl 1):P149
Background:
Cluster headache (CH), one of the most painful conditions known to
humans, can occur secondary to pituitary disease. To date, it remains
unclear as to whether a higher prevalence of pituitary tumours exists
in CH patients and, as a result, if pituitary imaging is required in the
diagnostic assessment of CH patients. The aim of this study was to
determine the incidence of pituitary adenomas in CH patients and to
identify clinical predictors of pituitary adenomas in CH patients.
Methods:
A retrospective study was conducted of all consecutive patients diag-
nosed with CH between 2007 and 2017 in a headache center. Data
including demographics, attack characteristics, response to treat-
ments and routine pituitary function tests were recorded. Univariate
and multivariate analysis using random forests were used to analyse
the data.
Results:
718 CH patients attended the headache clinic; 643 underwent a
standard MRI scan of whom 376 also underwent a dedicated pituit-
ary MRI. Pituitary adenomas occurred in 17 of 376 patients (4.52%).
Non-functioning microadenomas (n=13) were the most common ab-
normality reported. Two patients, one of whom lacked the symptoms
of pituitary disease, required treatment for their pituitary lesion. No
statistical difference was found between patients with pituitary aden-
oma and with normal pituitary MRI in terms of demographic, clinical
characteristic or response to treatment. Systematic pituitary MRI
scanning only benefited a single patient in the entire cohort.
Conclusion:
The incidence of pituitary adenomas in CH is similar to that reported
in the general population thereby precluding an over-representation
of pituitary lesions in CH. We conclude that the diagnostic assess-
ment of CH patients should not include routine pituitary screening.
Only patients with standard brain MRI findings or symptoms suggest-
ive of a pituitary disorder require pituitary imaging.
Classification of evidence:
This study provides Class IV evidence that routine dedicated pituitary
MRI scans are not indicated in CH patientsPreventive treatment, V41: Follow-up duration
